Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
e-Letters: Observations

Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability

  1. Yuki Nakatani1⇑,
  2. Atsuhiko Kawabe2,
  3. Mihoko Matsumura3,
  4. Yoshimasa Aso3,
  5. Takanori Yasu2,
  6. Nobuyuki Banba1 and
  7. Takaaki Nakamoto2
  1. 1Department of Diabetes and Endocrinology, Dokkyo Medical University Nikko Medical Center, Tochigi, Japan
  2. 2Department of Cardiovascular Medicine, Dokkyo Medical University Nikko Medical Center, Tochigi, Japan
  3. 3Department of Endocrinology and Metabolism, Dokkyo Medical University, Tochigi, Japan
  1. Corresponding author: Yuki Nakatani, yu-naka{at}dokkyomed.ac.jp.
Diabetes Care 2016 Feb; 39(2): e22-e23. https://doi.org/10.2337/dc15-1437
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Long- and short-acting glucagon-like peptide 1 receptor agonists (GLP-1RAs) liraglutide and lixisenatide, which are available for diabetes therapy, may act on the autonomic nervous system to increase heart rate (1,2). We performed a prospective, single-center, randomized, open-label study with a 1:1 allocation ratio using a 24-h Holter electrocardiogram to compare the effects of these GLP-1RAs on the autonomic nervous system. All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. Informed consent was obtained from all patients participating in this study. The study is registered at University Hospital Medical Information Network Clinical Trials Registry (UMIN000017770).

Sixty patients with type 2 diabetes who were admitted for diabetes treatment and had not received dipeptidyl peptidase-4 inhibitors or GLP-1RAs were randomly divided into a liraglutide (age 64.9 ± 12.7 years, HbA1c 10.3 ± 2.5% [89.1 mmol/mol], BMI 24.6 ± 4.8 kg/m2, diabetes duration 7.8 ± 7.8 years) or lixisenatide group (age 62.1 ± 15.6 years, HbA1c 10.7 ± 2.3% [93.4 mmol/mol], BMI 25.2 ± 2.1 kg/m2, diabetes duration 7.2 ± 6.6 years) after completing a 24-h Holter electrocardiography recording. There were no differences in the baseline characteristics between the groups. Three patients in each group had a previous history of coronary vascular events.

Liraglutide administration was by titration starting at 0.3 mg and increasing by 0.3 mg every week until reaching 0.9 mg. Lixisenatide administration started at 10 µg and increased by 5 µg every week until reaching 20 µg. After the maximum dose of the drugs had continued for 1 week or more, the Holter electrocardiography was repeated. Each component at a frequency of 0.04–0.15 Hz was regarded as low frequency (LF), and at 0.2–0.4 Hz, high frequency (HF). The LF/HF ratio was calculated by power spectral analysis with a sampling time of 1,024 s and then performed at 30-min intervals using an R-R interval spectral analysis.

Mean daily heart rates using Holter electrocardiography increased significantly from baseline in the liraglutide group at all times (66.5 ± 10.2 to 79.7 ± 10.5 bpm, P = 0.00021). By contrast, heart rates of the lixisenatide group increased significantly after only 5 h following administration of lixisenatide (09:00–13:00 h, P = 0.001 to 0.015), but mean heart rates per day remained unchanged (69.1 ± 8.6 to 71.7 ± 10.6 bpm, P = 0.172) (Fig. 1). In the liraglutide group, significant differences were observed in 16 of the 24 points examined in the LF/HF ratio (mean 1.58 ± 0.78 to 1.95 ± 0.89, P = 0.017), whereas in the lixisenatide group, no significant changes were found in the LF/HF ratio from the baseline value at any point (mean 1.95 ± 1.16 to 1.75 ± 0.74, P = 0.330).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Diurnal profile of heart rate changes in patients with type 2 diabetes at baseline and after treatment with liraglutide or lixisenatide. Data are mean ± SD. ‡P < 0.05, †P < 0.01, *P < 0.001 vs. baseline

Previous studies have indicated that liraglutide increases the heart rate by sympathetic nervous system enhancement (3), which would suggest that similar increases of heart rate due to sympathetic nervous system enhancement should also increase the LF/HF ratio in the lixisenatide group during the same hours. However, no such changes were detected, suggesting that another mechanism is involved in heart rate increase. Recent studies report that GLP-1 receptors are distributed at the sinoatrial node of the heart (4,5). This is consistent with the finding that lixisenatide increases heart rates only during its action duration without increasing the LF/HF ratio. Liraglutide may have markedly increased heart rates through the persistent, relative sympathetic enhancements, but sinoatrial node stimulation was also present during the pharmacological action duration, similar to lixisenatide. As a result, heart rate may have increased more markedly at night when parasympathetic activity is predominant. Increases in heart rate associated with GLP-1RAs have been attributed to relative sympathetic enhancements related to the inhibition of the autonomic nervous system, especially the parasympathetic nervous system. The current results suggest that not only relative sympathetic enhancements but also direct sinoatrial node stimulation contribute to GLP-1RA–related increases in heart rate.

Article Information

Acknowledgments. The authors thank the patients who participated in the study as well as the nursing stuff in their hospital.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. A.K. performed Holter electrocardiography. M.M. and Y.A. reviewed the manuscript. T.Y. performed the statistical analysis and reviewed the manuscript. N.B. collected data and edited the manuscript. T.N. was responsible for the medical supervision of this study. Y.N. was involved in the clinical conduct of this study and writing the manuscript. Y.N. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation. This work was presented in abstract form at the 75th Scientific Sessions of the American Diabetes Association, Boston, MA, 5–9 June 2015.

Footnotes

  • Clinical trial reg. no. UMIN000017770, www.umin.ac.jp/ctr.

  • Received July 3, 2015.
  • Accepted October 31, 2015.
  • © 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

References

  1. ↵
    1. Barragán JM,
    2. Eng J,
    3. Rodríguez R,
    4. Blázquez E
    . Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol 1999;277:E784–E791
    OpenUrlPubMed
  2. ↵
    1. Yamamoto H,
    2. Lee CE,
    3. Marcus JN, et al
    . Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002;110:43–52
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Meier JJ,
    2. Rosenstock J,
    3. Hincelin-Méry A, et al
    . Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care 2015;38:1263–1273
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Pyke C,
    2. Heller RS,
    3. Kirk RK, et al
    . GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014;155:1280–1290
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Kim M,
    2. Platt MJ,
    3. Shibasaki T, et al
    . GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013;19:567–575
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Diabetes Care: 39 (2)

In this Issue

February 2016, 39(2)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability
Yuki Nakatani, Atsuhiko Kawabe, Mihoko Matsumura, Yoshimasa Aso, Takanori Yasu, Nobuyuki Banba, Takaaki Nakamoto
Diabetes Care Feb 2016, 39 (2) e22-e23; DOI: 10.2337/dc15-1437

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability
Yuki Nakatani, Atsuhiko Kawabe, Mihoko Matsumura, Yoshimasa Aso, Takanori Yasu, Nobuyuki Banba, Takaaki Nakamoto
Diabetes Care Feb 2016, 39 (2) e22-e23; DOI: 10.2337/dc15-1437
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Creating Composite Indices From Continuous Variables for Research: The Geometric Mean
  • Vertebral Ischemic Necrosis in Diabetic Lumbosacral Radiculoplexus Neuropathy
  • Degree of Cardiometabolic Risk Factor Normalization in Individuals Receiving Bariatric Surgery: Evidence From NHANES 2015–2018
Show more e-Letters: Observations

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.